鹰瞳科技-B2024年中期报告

CONTENTS PageCorporate Information2Financial Summary5Management Discussion and Analysis6Other Information38Independent Review Report59Interim Condensed Consolidated Statement ofProfit or Loss61Interim Condensed Consolidated Statement ofComprehensive Income62Interim Condensed Consolidated Statement ofFinancial Position63Interim Condensed Consolidated Statement ofChanges in Equity65Interim Condensed Consolidated Statement ofCash Flows66Notes to Interim Condensed ConsolidatedFinancial Information70Definitions and Glossary of Technical Terms100 CORPORATE INFORMATION BOARD OF DIRECTORS Executive Directors Mr. ZHANG Dalei ()(Chairman and chief executive officer)Ms. WANG Lin ()Dr. HE Chao ()Mr. QIN Yong () Independent Non-executive Directors 20248 28 Mr. NG Kong Ping Albert ()(resigned on August 28, 2024)Dr. WU Yangfeng ()Dr. HUANG Yanlin () SUPERVISORS Mr. WEI Yubo ()Ms. BAI Huihui ()Dr. LUO Ting () AUDIT COMMITTEE 20248 28 Mr. NG Kong Ping Albert ()(Chairman)(resigned on August 28, 2024)Dr. HUANG Yanlin ()Dr. WU Yangfeng () REMUNERATION AND APPRAISALCOMMITTEE 20248 28 Dr. HUANG Yanlin ()(Chairman)Mr. NG Kong Ping Albert ()(resigned on August 28, 2024)Ms. WANG Lin () NOMINATION COMMITTEE Mr. ZHANG Dalei ()(Chairman)Dr. HUANG Yanlin ()Dr. WU Yangfeng () STRATEGY COMMITTEE Mr. ZHANG Dalei ()(Chairman)Mr. NG Kong Ping Albert ()(resigned on August 28, 2024)Dr. WU Yangfeng () 20248 28 ESG COMMITTEE Mr. ZHANG Dalei ()(Chairman)Ms. WANG Lin ()Dr. HE Chao () AUTHORIZED REPRESENTATIVES Mr. ZHANG Dalei ()Ms. SO Lai Shan () JOINT COMPANY SECRETARIES Ms. YANG Wenting ()Ms. SO Lai Shan ()(ACG (CS, CGP) HKACG (CS, CGP)) HEAD OFFICE, REGISTERED OFFICE ANDPRINCIPAL PLACE OF BUSINESS IN THEPRC 22421 Room 21, 4th Floor, Building 2, A2 YardWest Third Ring North RoadHaidian DistrictBeijingPRC PRINCIPAL PLACE OF BUSINESS IN HONGKONG 33191901 Room 1901, 19/F, Lee Garden One33 Hysan AvenueCauseway BayHong Kong CORPORATE INFORMATION H H SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong HONG KONG LEGAL ADVISER 1526 Kirkland & Ellis26/F, Gloucester TowerThe Landmark15 Queen’s Road CentralHong Kong PRC LEGAL ADVISER 2022–31 Zhong Lun Law Firm22–31/F, South Tower of CP Center20 Jin He East AvenueChaoyang DistrictBeijingPRC AUDITOR 97927 Ernst & Young Certified Public AccountantsRegistered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry BayHong Kong STOCK CODE 2251 2251 COMPANY WEBSITE www.airdoc.com www.airdoc.com FINANCIAL SUMMARY財務概要 MANAGEMENT DISCUSSION AND ANALYSIS BUSINESS OVERVIEW (SaMD) As an industry pioneer, we are focused on leveraging AItechnology to provide comprehensive solutions for earlydetection, diagnosis and health risk assessment of chronicfundus and ophthalmic diseases, while also offering eyehealth management services such as myopia prevention andvisual training. Our proprietary AI-empowered retina-baseddeep algorithm platform holds a leading position in thei n d u s t r y ,m a k i n g u s o n e o f t h e f i r s t t o p r o v i d eAI-empowered retina-based early detection, diagnosis andhealth risk assessment solutions in China. Our pipelineincludes AI-based SaMDs, health risk assessment solutionsand compatible AI hardware devices, designed to cater tomedical institutions and consumer healthcare environments,based on which we developed an integrated solution thatcombines both software and hardware components.Additionally, we have launched AI-empowered treatmentproducts targeting myopia, strabismus, and amblyopia inchildren and adolescents, achieving a one-stop solution thatranges from detection to assessment to treatment. This notonly enables us to expand our commercial activities fromdetection to treatment, but also strengthens our channelmanagement and synergistic effects, which broadens themarket coverage of our products, extending beyond theclinical departments of hospitals to serve a wider range ofp r i m a r y h e a l t h c a r e i n s t i t u t i o n s , c o n s u m e r h e a l t henvironments, and eye health management settings. 3,3315,95078.6%SaMD20242.96202363082.593.713.6% Upholding the mission of “Accessible and Affordable toEveryone”, we are steadfast in expanding our service sites,enhancing the volume of detections and treatments, andthereby realizing substantial growth in revenue. In theprocess of our continual efforts in optimizing marketingstrategy, during the Reporting Period, the number of ouractive service sites grew from 3,331 to 5,950, representing ayear-over-year increase of 78.6%. Through our SaMDs andhealth risk assessment solutions, we detected 2.96 millioncases in the first half of 2024. Additionally, our revenueincreased from RMB82.5 million for the six months endedJune 30, 2023 to RMB93.7 million for the Reporting Period,representing a year-over-year growth of 13.6%. 29.836.522.1%31.038.022.7%2.9615,8427 Our revenue growth is mainly attributed to